The trial was an excellent demonstration of the success of WCCT’s hybrid model which combines using well known ophthalmology researchers who screened subjects at their offices and scheduled their overnights at the WCCT overnight facilities. In little over 2 months, WCCT enrolled the ophthalmic study which captured PK data, serial interocular readings, and ethnic data (7 of the 31 subjects were Japanese glaucoma patients) in a 2 way crossover design.
WCCT Chief Operating Officer, Jon Rojas, noted that study sponsors are increasingly trying to combine phase 2a efficacy pharmacodynamic or biomarker endpoints, and this study design utilizing patient populations in phase I is become more the norm than the standard healthy volunteer model. WCCT has developed a particularly strong ophthalmic database and network of partnered established ophthalmic clinical researchers, and has been identified by a number of sponsors as the best place to place specialized ophthalmic phase I trials.
About West Coast Clinical Trials, LLC
West Coast Clinical Trials (WCCT) is a private minority-owned independent Phase I-IV Clinical Research Organization located in Southern California. WCCT has 150 beds in two locations, over 40,000 square feet, and a well-trained and experienced staff bringing the highest quality to the pharmaceutical and biotechnology industries.
WCCT was founded by Dr. Kenneth Kim who is board certified in Internal Medicine and Allergy and Immunology. WCCT has been conducting trials since 1998 and has been audited by the FDA and numerous pharmaceutical and biotechnology companies. Our location and access to an ethnically diverse population allows us to conduct a wide variety of studies designs including ethnic bridging, and specialty trials.
Contact information:
West Coast Clinical Trials
5630 Cerritos Ave.
Cypress, CA 90630 USA
Phone: (714) 252-0700
E-mail: mgr@wcct.com
http://wcct.com
